Shield Therapeutics Plc (SHIEF)

$0.10 +0.06 (150.91%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 100
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 44 1915 118 500
Address:
Northern Design Centre, Baltic Business Quarter, Gateshead, United Kingdom
MrMoneyMan93
MrMoneyMan93 May. 28 at 8:26 PM
$SHIEF sink or swim? We find out this year
0 · Reply
fda_tracker
fda_tracker Apr. 4 at 1:05 PM
$SHIEF Phase 3 trial w/est Apr completion date NCT05126901: https://www.clinicaltrials.gov/study/NCT05126901 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker May. 26 at 1:05 PM
$SHIEF Phase 3 trial w/est May completion date NCT05126901: http://clinicaltrials.gov/ct2/show/NCT05126901 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
BarTwit
BarTwit Apr. 20 at 5:54 AM
$VTRS $SHIEF Shield therapeutics to announce yr end results for ‘22 next week, the 27 April and to provide an investor presentation. In this interview CEO Greg Maddison expresses his delight that the collaboration with Viatris is.. “of to a great start” https://youtu.be/d45VZtnJJhs
1 · Reply
BarTwit
BarTwit Apr. 17 at 4:19 PM
$VTRS $SHIEF Shield therapeutics, the UK company partnered with Viatris to break into a 2 billion dollar under-served market has announced that it will announce its final results for the year ended 31 December 2022 on Thursday 27 April 2023 and an Investor presentation. This announcement seems earlier than expected (it could have been left until end of June) and therefore implies that the bullish CEO Greg Maddison may have something to crow about, what’s good for Shield Therapeutics could also be good for Viatris Viatris deal has the potential to accelerate sales at a much faster rate If they show signs of revenue build and keep with the bullish sentiment going forward this could treble at least from this level https://*************.net/shield-therapeutics-viatris-deal-has-the-potential-to-accelerate-sales-at-a-much-faster-rate-lonstx
1 · Reply
Latest News on SHIEF
No data available.
MrMoneyMan93
MrMoneyMan93 May. 28 at 8:26 PM
$SHIEF sink or swim? We find out this year
0 · Reply
fda_tracker
fda_tracker Apr. 4 at 1:05 PM
$SHIEF Phase 3 trial w/est Apr completion date NCT05126901: https://www.clinicaltrials.gov/study/NCT05126901 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker May. 26 at 1:05 PM
$SHIEF Phase 3 trial w/est May completion date NCT05126901: http://clinicaltrials.gov/ct2/show/NCT05126901 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
BarTwit
BarTwit Apr. 20 at 5:54 AM
$VTRS $SHIEF Shield therapeutics to announce yr end results for ‘22 next week, the 27 April and to provide an investor presentation. In this interview CEO Greg Maddison expresses his delight that the collaboration with Viatris is.. “of to a great start” https://youtu.be/d45VZtnJJhs
1 · Reply
BarTwit
BarTwit Apr. 17 at 4:19 PM
$VTRS $SHIEF Shield therapeutics, the UK company partnered with Viatris to break into a 2 billion dollar under-served market has announced that it will announce its final results for the year ended 31 December 2022 on Thursday 27 April 2023 and an Investor presentation. This announcement seems earlier than expected (it could have been left until end of June) and therefore implies that the bullish CEO Greg Maddison may have something to crow about, what’s good for Shield Therapeutics could also be good for Viatris Viatris deal has the potential to accelerate sales at a much faster rate If they show signs of revenue build and keep with the bullish sentiment going forward this could treble at least from this level https://*************.net/shield-therapeutics-viatris-deal-has-the-potential-to-accelerate-sales-at-a-much-faster-rate-lonstx
1 · Reply